Heart drug trial aims to shield boys from Duchenne's deadly heart damage
NCT ID NCT01648634
Summary
This study tested whether a blood pressure/heart rate medication called nebivolol could prevent heart muscle weakness in boys with Duchenne muscular dystrophy. It involved 51 boys aged 10-15 who still had good heart function. Participants were randomly assigned to receive either the real medication or a placebo pill for two years to see if the drug could delay the heart damage common in this disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Armand Trousseau Hospital
Paris, 75012, France
Conditions
Explore the condition pages connected to this study.